Sociedad Americana de Hirudoterapia

The place of chemical leeching with heparin in digital replantation

Technique paper published in Plastic and Reconstructive Surgery (2007)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportDesarrollo de fármacosEnsayos clínicosYokoyama T et al. · Plastic and reconstructive surgery, 2007

Abstract

BACKGROUND: In patients with replanted digits, systemic heparinization or other techniques may be used for prevention of thrombosis of the vascular anastomoses or to prevent coagulation at the drainage site (e.g., a fish-mouth incision or partially removed nail). However, systemic heparin may be contraindicated or require cautious administration in certain patients. The authors injected calcium heparin subcutaneously into the congested replanted digits of seven patients with a history of or undergoing treatment for hemorrhoids or gastric ulcer and drained the congestion by means of a fish-mouth incision. METHODS: With this method, 0.8 ml (20,000 U) of calcium heparin for subcutaneous injection was diluted with 1.2 ml of saline to prepare a solution containing 1000 U in 0.1 ml; this calcium heparin solution (1000 U) was initially injected into the tip of the congested digit. If required, additional doses of 500 U each were administered every 24 hours until the congestion improved. RESULTS: No worsening of bleeding from hemorrhoids or gastric ulcer was seen after the administration of calcium heparin in these patients. Regarding duration of action, continuous bleeding for approximately 6 hours was obtained after subcutaneous injection of 1000 U, and thereafter, adequate drainage was achieved for approximately 24 hours by stimulating the drainage site. CONCLUSIONS: Among patients in whom systemic heparin is contraindicated or who require cautious administration, this is a very effective technique in those in whom congestion fails to improve despite thrombectomy, patients in whom thrombectomy or vascular reanastomosis is not possible, and patients with congestion caused by narrow anastomosed veins.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultAmputation, TraumaticCohort StudiesContraindicationsDose-Response Relationship, DrugDrug Administration ScheduleFinger InjuriesHeparinHumansInfusions, IntravenousInjections, SubcutaneousMale

Resumen

Describes subcutaneous calcium heparin injection at congested replanted digit tip as 'chemical leech' alternative for patients in whom systemic heparin is contraindicated.

Por qué esto importa para la hirudoterapia

Este estudio describió una técnica en la que se inyectó heparina cálcica por vía subcutánea en dedos reimplantados congestionados de siete pacientes en quienes la heparina sistémica estaba contraindicada o requería una administración cautelosa, con drenaje de la congestión mediante una incisión en boca de pez. Se logró un drenaje adecuado sin empeoramiento del sangrado por condiciones como hemorroides o úlceras gástricas. El resumen no menciona sanguijuelas, hirudoterapia ni ninguna sustancia derivada de sanguijuela. Por lo tanto, la relevancia para ASH es negligible; el estudio se refiere a una técnica quirúrgica de manejo del sangrado que involucra heparina y no incluye ni compara con la terapia con sanguijuelas.

Citación

The place of chemical leeching with heparin in digital replantation.

Yokoyama T et al. · Plastic and reconstructive surgery, 2007

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.